Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 13/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7100236 | 1.00 | ESR1 (0.46) | ESR1ARESR2CYP19A1SRD5A2 | |
| SCHEMBL6899597 | 1.00 | ESR1 (0.46) | ESR1ARESR2CYP19A1SRD5A2 | |
| SCHEMBL1044379 | 0.86 | CYP19A1 (0.60) | CYP19A1SRD5A2 | |
| SCHEMBL8245517 | 0.86 | CYP19A1 (0.60) | CYP19A1SRD5A2 | |
| SCHEMBL5310190 | 0.86 | CYP19A1 (0.60) | CYP19A1SRD5A2 | |
| SCHEMBL9623706 | 0.83 | ESR1 (0.44) | ESR1ARESR2CYP19A1SRD5A2 | |
| SCHEMBL10444899 | 0.83 | ESR1 (0.44) | ESR1ARESR2CYP19A1SRD5A2 | |
| SCHEMBL15079256 | 0.83 | ESR1 (0.44) | ESR1ARESR2CYP19A1SRD5A2 | |
| SCHEMBL8818873 | 0.83 | ESR1 (0.49) | ESR1ARESR2CYP19A1SRD5A2 | |
| SCHEMBL10380160 | 0.82 | ESR1 (0.45) | ESR1ARESR2CYP19A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340502-A2 | Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods | PHERIN CORPORATION (US) | 2003-09-03 | — | — | EP | claimed |
| US-20020103391-A1 | Novel androstanes for inducing hypothalamic effects | BERLINER DAVID L (US) | 2002-08-01 | — | — | US | claimed |
| US-5969168-A | STIMULATE AUTONOMIC ACTIVITY | PHERIN CORPORATION (US) | 1999-10-19 | — | — | US | claimed |
| EP-0783512-A4 | NOVEL ANDROSTANES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN CORP (US) | 1998-09-02 | — | — | EP | claimed |
| EP-0783512-A1 | NOVEL ANDROSTANES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN CORPORATION (US) | 1997-07-16 | — | — | EP | claimed |
| WO-1996010031-A1 | NOVEL ANDROSTANES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN CORPORATION (US) | 1996-04-04 | — | — | WO | claimed |
| EP-0891188-A4 | STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH | PHERIN PHARM INC (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20020103391-A1 | Novel androstanes for inducing hypothalamic effects | BERLINER DAVID L (US) | 2002-08-01 | — | — | US | disclosed |
| US-6331534-B1 | ADMINISTERING EFFECTIVE AMOUNT OF STEROID WITHIN NASAL PASSAGE OF INDIVIDUAL SUCH THAT IT BINDS SPECIFICALLY TO RECEPTORS ON SURFACE OF NASAL NEUROEPITHELIAL CELLS IN VOMERONASAL ORGAN | PHERIN PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| US-6117860-A | NASALLY ADMINISTERING STEROID WHICH BINDS TO A SPECIFIC NEUROEPITHELIAL RECEPTOR FOR ALLEVIATING PREMENSTRUAL TENSION AND ANXIETY | PHERIN PHARMACEUTICALS, INC. (US) | 2000-09-12 | — | — | US | disclosed |
| US-6066627-A | ALTERING BLOOD CONCNETRATION OF LUTEINIZING HORMONE | PHERIN CORPORATION (US) | 2000-05-23 | — | — | US | disclosed |
| US-6057439-A | EPOXYSTEROIDS | PHERIN CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-5969168-A | STIMULATE AUTONOMIC ACTIVITY | PHERIN CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0891188-A1 | STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH | Pherin Pharmaceuticals, Inc. (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1998014194-A9 | STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF ANXIETY | — | 1998-08-27 | — | — | WO | disclosed |
| WO-1997036596-A9 | STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH | — | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103391-A1 | Novel androstanes for inducing hypothalamic effects | FABP7, NR3C2, NR3C1 | ESR1 265/4885AR 178/4885ESR2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.